Therapeutic experience with tramadol for opioid dependence: A prospective observational study from India

Kirti Sharma; Prabhoo Dayal; Siddharth Sarkar; Sonali Jhanjee

doi:10.5055/jom.0898

Authors

Kirti Sharma, MD
Prabhoo Dayal, MD https://orcid.org/0000-0003-0801-1559
Siddharth Sarkar, MD
Sonali Jhanjee, MD

DOI:

https://doi.org/10.5055/jom.0898

Keywords:

opioid use disorder, tramadol, days of opioid use, retention

Abstract

Introduction: Opioid use disorder (OUD) is a chronic relapsing disorder with significant mortality, morbidity, and public health challenges. In India, tramadol is frequently used for the treatment and management of OUDs.

Methodology: A prospective observational study was performed to evaluate 3-month outcomes in outpatients with OUD on treatment with tramadol at a tertiary care addiction treatment facility in North India. One hundred and sixty newly registered patients fulfilling the inclusion and exclusion criteria were recruited and assessed on Maudsley Addiction Profile to evaluate changes in days and the amount of substance use and associated complications at 1-, 2-, and 3-month follow-up.

Results: This study also showed a treatment retention rate of 14 percent with an abstinence rate of 34 percent at the end of the third month. The mean number of days of illicit opioid use in retained population decreased from 29.3 (±3.5) days from baseline to 12.5 (±10.9) days at 1 month, 5.0 (±7.2) days at 2 months, and 4.3 (±6.8) days at 3 months. Repeated measures analyses showed significant change in the days of illicit opioid use on treatment with tramadol over 3 months (p = 0.01).

Conclusion: This study leads the way in showing tramadol as an important medication for use in OUDs to provide for maintenance therapy for longer durations. This has major implications in low- and middle-income countries, especially in Asia and Africa, where tramadol is more easily available.

Author Biographies

Kirti Sharma, MD

Senior Resident, National Drug Dependence Treatment Centre (NDDTC); Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Prabhoo Dayal, MD

Corresponding Author, Additional Professor of Psychiatry, National Drug Dependence Treatment Centre (NDDTC); Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Siddharth Sarkar, MD

Additional Professor of Psychiatry, National Drug Dependence Treatment Centre (NDDTC); Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Sonali Jhanjee, MD

Professor, National Drug Dependence Treatment Centre (NDDTC); Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India

References

Strang J, Volkow ND, Degenhardt L, et al.: Opioid use disorder. Nat Rev Dis Primers. 2020; 6(1): 3. DOI: 10.1038/s41572-019-0137-5.

Kampman K, Jarvis M: American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addiction Med. 2015; 9(5): 358-367. DOI: 10.1097/ADM.0000000000000166.

Rao R: The journey of opioid substitution therapy in India: Achievements and challenges. Indian J Psychiatry. 2017; 59(1): 39. DOI: 10.4103/psychiatry.IndianJPsychiatry_37_17.

Degenhardt L, Grebely J, Stone J, et al.: Global patterns of opioid use and dependence: Harms to populations, interventions, and future action. Lancet. 2019; 394(10208): 1560-1579. DOI: 10.1016/S0140-6736(19)32229-9.

Ambekar A, Agrawal A, Rao R, et al.: Magnitude of Substance Use in India. Delhi: Ministry of Social Justice and Empowerment, Government of India, 2019.

Balhara YPS, Parmar A, Sarkar S: Use of tramadol for management of opioid use disorders: Rationale and recommendations. J Neurosci Rural Practice. 2018; 9(3): 397-403. DOI: 10.4103/jnrp.jnrp_42_18.

Sarkar S, Lal R, Varshney M, et al.: Can tramadol be used for maintenance treatment of opioid dependence? Substance Use Misuse. 2019; 54(3): 506-513. DOI: 10.1080/10826084.2018.1521427.

Marsden J, Gossop M, Stewart D, et al.: The Maudsley Addiction Profile (MAP): A brief instrument for assessing treatment outcome. Addiction (Abingdon, England). 1998; 93(12): 1857-1867. DOI: 10.1046/j.1360-0443.1998.9312185711.x.

Singh VV, Sarkar S, Chadda RK, et al.: Reasons for leaving treatment among patients with opioid dependence: A 3-month prospective follow-up study. J Opioid Manag. 2022; 18(5): 455-466. DOI: 10.5055/jom.2022.0739.

Chan B, Gean E, Arkhipova-Jenkins I, et al.: Retention strategies for medications for opioid use disorder in adults: A rapid evidence review. J Addict Med. 2021; 15(1): 74-84. DOI: 10.1097/ADM.0000000000000739.

Sarkar S, Lal R, Varshney M, et al.: Tramadol for maintenance in opioid dependence: A retrospective chart review. J Opioid Manag. 2017; 13(5): 329-334. DOI: 10.5055/jom.2017.0401.

Dhawan A, Chopra A: Does buprenorphine maintenance improve the quality of life of opioid users? Indian J Med Res. 2013; 137(1): 130-135.

Dayal P, Balhara YPS: A naturalistic study of predictors of retention in treatment among emerging adults entering first buprenorphine maintenance treatment for opioid use disorders. J Substance Abuse Treat. 2017; 80: 1-5. DOI: 10.1016/j.jsat.2017.06.004.

Dayal P, Balhara YPS, Mishra AK: An open label naturalistic study of predictors of retention and compliance to naltrexone maintenance treatment among patients with opioid dependence. J Substance Use. 2016; 21(3): 309-316. DOI: 10.3109/14659891.2015.1021867.

Chand P, Murthy P: Short-term outcome of take-home prescriptions for opioid dependence: A clinic-based study. J Substance Use. 2013; 18(2): 108-118. DOI: 10.3109/14659891.2011.615882.

Shouan A, Ghosh A, Singh SM, et al.: Predictors of retention in the treatment for opioid dependence: A prospective, observational study from India. Indian J Psychiatry. 2021; 63(4): 355-365. DOI: 10.4103/psychiatry.IndianJPsychiatry_448_20.

Chawla JM, Pal H, Lal R, et al.: Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects. J Opioid Manag. 2013; 9(1): 35-41. DOI: 10.5055/jom.2013.0145.

Tamaskar R, Parran TV, Heggi A, et al.: Tramadol versus buprenorphine for the treatment of opiate withdrawal: A retrospective cohort control study. J Addictive Dis. 2004; 22(4): 5-12. DOI: 10.1300/J069v22n04_02.

Threlkeld M, Threlkeld M, Parran TV, et al.: Tramadol versus buprenorphine for the management of acute heroin withdrawal: A retrospective matched cohort controlled study. Am J Addict. 2006; 15(2): 186-191. DOI: 10.1080/10550490500528712.

Majumder P, Sarkar S, Gupta R, et al.: Predictors of retention in treatment in a tertiary care de-addiction center. Indian J Psychiatry. 2016; 58(1): 27. DOI: 10.4103/0019-5545.174359.

Pandit PM, Bhatia G, Sarkar S: Treatment experience for opioid use disorder during COVID-19 in India: Learning from patients. J Substance Abuse Treat. 2020; 119: 108128. DOI: 10.1016/j.jsat.2020.108128.

Oesterle TS, Thusius NJ, Rummans TA, et al.: Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019; 94(10): 2072-2086. DOI: 10.1016/j.mayocp.2019.03.029.